The CRF1 antagonist verucerfont in anxious alcohol-dependent women: Translation of neuroendocrine, but not of anti-craving effects

Neuropsychopharmacology

Volumn 41, Issue 12, 2016, Pages 2818-2829

  Schwandt, Melanie L ^a   Cortes, Carlos R ^a,e   Kwako, Laura E ^a   George, David T ^a   Momenan, Reza ^a   Sinha, Rajita ^b   Grigoriadis, Dimitri E ^c   Pich, Emilio Merlo ^d   Leggio, Lorenzo ^a   Heilig, Markus ^a,e  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEUROCRINE BIOSCIENCES INC   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR; DEXAMETHASONE; HYDROCORTISONE; PEXACERFONT; PLACEBO; VERUCERFONT; AZABICYCLO DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; OXADIAZOLE DERIVATIVE; OXYGEN;

ADRENALECTOMY; ADULT; AGED; ALCOHOL WITHDRAWAL SYNDROME; ALCOHOLISM; AMYGDALA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GUIDED IMAGERY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VIVO STUDY; INSULA; INTERPERSONAL STRESS; NERVE STIMULATION; NEUROENDOCRINOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE BLIND PROCEDURE; SOCIAL STRESS; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; CRAVING; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; ETIOLOGY; IMAGE PROCESSING; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; SPRAGUE DAWLEY RAT; YOUNG ADULT;

ADRENALECTOMY; ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; ALCOHOLISM; ANIMALS; ANXIETY; AZABICYCLO COMPOUNDS; CRAVING; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGERY (PSYCHOTHERAPY); MIDDLE AGED; OXADIAZOLES; OXYGEN; PSYCHIATRIC STATUS RATING SCALES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84984681309     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.61     Document Type: Article

References (53)

1. Asberg M, Schalling D. (1979). Construction of a new psychiatric rating instrument, the Comprehensive Psychopathological Rating Scale (CPRS). Progr Neuro-Psychopharmacol 3: 405-412
2. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K., et al. (1994). Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 151: 1132-1136
3. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. (2008). A 6-week randomized, placebo-controlled trial of CP-316, 311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165: 617-620
4. Bohn MJ, Krahn DD, Staehler BA. (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19: 600-606
5. Brandon TH, Vidrine JI, Litvin EB. (2007). Relapse and relapse prevention. Annu Rev Clin Psychol 3: 257-284
6. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC., et al. (2010). Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropinreleasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27: 417-425
7. Costa PT, McCree RR. (2002). NEO Personality Inventory-Revised (NEO PI-R). APA: Washington, DC. Cox RW. (1996). AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 29: 162-173
8. First MB, Spitzer RL, Gibbon M, Williams JBW. (1996). Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press: Washington, DC
9. Flannery BA, Volpicelli JR, Pettinati HM. (1999). Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23: 1289-1295
10. Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE. (2012). Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther 341: 518-531
11. Foa EB, Riggs DS, Dancu CV, Rothbaum BO. (1993). Reliability and validity of a brief instrument for assessing posttraumatic-stressdisorder. J Trauma Stress 6: 459-473
12. Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM., et al. (2012). Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res 36: 351-360
13. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C., et al. (2008). Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319: 1536-1539
14. Gilligan PJ, Clarke T, He L, Lelas S, Li YW, Heman K., et al. (2009). Synthesis and structure-Activity relationships of 8-(pyrid-3-yl) pyrazolo[1, 5-A]-1, 3, 5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists. J Med Chem 52: 3084-3092
15. GlaxoSmithKline. (2010). Results Summary for CRS106139. A sixweek, multicenter, randomized, double-blind, placebo-controlled, parallel-group study valuating the efficacy, safety, and tolerability of GSK561679 compared to placebo in female subjects, diagnosed with major depressive disorder. Available at: http: // download.gsk-clinicalstudyregister.com/files/ee490a01-8433-4cba-A027-9c486b866a67. (date last accessed 16 May 2016
16. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, ComptonW., et al. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61: 807-816
17. Grillon C, Hale E, Lieberman L, Davis A, Pine DS, Ernst M. (2015). The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacology 40: 1064-1071
18. Hariri AR, Tessitore A, Mattay VS, Fera F, Weinberger DR. (2002). The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage 17: 317-323
19. Heilig M, Egli M. (2006). Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111: 855-876
20. Heilig M, Goldman D, Berrettini W, O'Brien CP. (2011). Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12: 670-684
21. Heilig M, Koob GF. (2007). A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30: 399-406
22. Heinz A, Lober S, Georgi A, Wrase J, Hermann D, Rey ER., et al. (2003). Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol 38: 35-39
23. Hunt WA, Barnett LW, Branch LG. (1971). Relapse rates in addiction programs. J Clin Psychol 27: 455-456
24. Kenward MG, Roger JH. (1997). Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53: 983-997
25. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC 1997). Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with ther psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 54: 313-321
26. Kirschbaum C, Pirke KM, Hellhammer DH. (1993). The ?Trier Social Stress Test?-A tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 76-81
27. Kwako LE, Schwandt ML, Sells JR, Ramchandani VA, Hommer DW, George DT., et al. (2014). Methods for inducing alcohol craving in individuals with co-morbid alcohol dependence and posttraumatic stress disorder: behavioral and physiological outcomes. Addict Biol 20: 733-746
28. Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R., et al. (2015). The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology 40: 1053-1063
29. Lang PJ, Bradley MM, Cuthbert BN. (1999). International Affective Picture System (IAPS): Technical Manual and Affective Ratings. The Center for Research in Psychophysiology, University of Florida: Gainesville, FL. Le A, Shaham Y. (2002). Neurobiology of relapse to alcohol in rats. Pharmacol Ther 94: 137-156
30. Le AD, Harding S, Juzytsch W, Fletcher PJ, Shaham Y. (2002). The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. J Neurosci 22: 7844-7849
31. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberge O. (2006). SAS for Mixed Models. Second Edition. SAS Institute Inc.: Cary, NC.
32. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML., et al. (2012). Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 17: 513-527
33. Liu X, Weiss F. (2002). Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropinreleasing factor and opioid mechanisms. J Neurosci 22: 7856-7861
34. Mann RE, Sobell LC, Sobell MB, Pavan D. (1985). Reliability of a family tree questionnaire for assessing family history of alcohol problems. Drug Alcohol Depend 15: 61-67
35. Mantsch JR, Baker DA, Funk D, Le AD, Shaham Y. (2016). Stressinduced reinstatement of drug seeking: 20 years of progress. Neuropsychopharmacology 41: 335-356
36. Matsumoto D, Ekman P. (1988). Japanese and Caucasian Facial Expressions of Emotion and Neutral Faces (JACFEE and JACNeuF) vol. 401 Human Interaction Laboratory, University of California: San Francisco, CA.
37. McLellan AT, Luborsky L, Woody GE, O'Brien CP. (1980). An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J NervMent Dis 168: 26-33
38. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, Holsboer F. (1998). Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 18: 253-262
39. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. (2002). Naltrexone decreases craving and alcohol self-Administration in alcohol-dependent subjects and activates the hypothalamo-pituitaryadrenocortical axis. Psychopharmacology (Berl) 160: 19-29.
40. Rivier JE, Kirby DA, Lahrichi SL, Corrigan A, Vale WW, Rivier CL. (1999). Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat. J Med Chem 42: 3175-3182
41. Rydmark I, Wahlberg K, Ghatan PH, Modell S, Nygren A, Ingvar M., et al. (2006). Neuroendocrine, cognitive and structural imaging characteristics of women on longterm sickleave with job stressinduced depression. Biol Psychiatry 60: 867-873
42. Simon GM, Niphakis MJ, Cravatt BF. (2013). Determining target engagement in living systems. Nat Chem Biol 9: 200-205
43. Sinha R, Fox HC, Hong KI, Hansen J, Tuit K, Kreek MJ. (2011). Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry 68: 942-952
44. Sinha R, Shaham Y, Heilig M. (2011). Translational and reverse translational research on the role of stress in drug craving and relapse. Psychopharmacology (Berl) 218: 69-82
45. Skinner HA. (1984). Assessing alcohol-use by patients in treatment. Res Adv Alcohol Drug 8: 183-207
46. Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E. (1986). The reliability of a timeline method for assessing normal drinker college students' recent drinking history: utility for alcohol research. Addict Behav 11: 149-161
47. Spielberger CD, Gorsuch RL, Lushene RE. (1970). STAI Manual for the Stait-Trait Anxiety Inventory (?Self-Evaluation Questionnaire?). Consulting Psychologists Press: Palo Alto, CA. 24pp.
48. Stasiewicz PR, Gulliver SB, Bradizza CM, Rohsenow DJ, Torrisi R, Monti PM 1997). Exposure to negative emotional cues and alcohol cue reactivity with lcoholics: a preliminary investigation. Behav Res Ther 35: 1143-1149
49. Tellew JE, Lanier M, Moorjani M, Lin E, Luo Z, Slee DH., et al. (2010). Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Bioorg Med Chem Lett 20: 7259-7264
50. Wolpe J. (1969). The Practice of Behavior Therapy, 1st edn. Pergamon Press: New York, NY, USA, 314pp.
51. Zhou L, Dockens RC, Liu-Kreyche P, Grossman SJ, Iyer RA. (2012). In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropinreleasing factor-1 receptor antagonist. Drug Metab Dispos 40: 1093-1103
52. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M., et al. (2000). Effects of the high-Affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34: 171-181
53. Zorrilla EP, Heilig M, De Wit H, Shaham Y. (2013). Behavioral, biological, and hemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend 128: 175-186